Non-24 may present itself differently for every patient1

  • Symptoms of Non-24 vary, based on an individual's unique circadian cycle

Norman

  • Retired, 57 years of age
  • Totally blind since birth
    “I am retired, so I have the ability to sleep when my body tells me it’s time, but it’s the staying up all night and the inability to commit to big family events and appointments that affects me the most.”

Becky

  • Mother, 39 years of age
  • Lost sight due to diabetic retinopathy
  • Totally blind for 15 years
    “With 2 kids, I do not have the luxury to design my day around my need to sleep, but my lack of sleep makes it tough to keep up and takes a toll on my relationship with my family.”

Jonathan

  • Social worker, 45 years of age
  • Totally blind since birth
    “The hardest part about my sleep-wake issues is how they affect my job. With a heavy caseload, I try desperately to maintain a 9 to 5 schedule, but find myself taking catnaps at my desk.”
Hypothetical patients based on the DSM-5 and the ICSD3.
Questions to help diagnose Non-24
Non-24 is highly prevalent in the totally blind

Reference: American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.

Expand Collapse

Important Safety Information

The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® (tasimelteon) than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.

Indication

HETLIOZ® is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Important Safety Information

  • HETLIOZ® may cause somnolence: After taking HETLIOZ®, patients should limit their activity to preparing for going to bed, because HETLIOZ® can potentially impair the performance of activities requiring complete mental alertness.
  • The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ® than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection. The risk of adverse reactions may be greater in elderly (>65 years) patients than younger patients because exposure to HETLIOZ® is increased by approximately 2-fold compared with younger patients.
  • Use of HETLIOZ® should be avoided in combination with fluvoxamine or other strong CYP1A2 inhibitors, because of a potentially large increase in exposure of HETLIOZ®, and a greater risk of adverse reactions. HETLIOZ® should be avoided in combination with rifampin or other CYP3A4 inducers, because of a potentially large decrease in exposure of HETLIOZ®, with reduced efficacy.
  • There are no adequate and well-controlled studies of HETLIOZ® in pregnant women. Based on animal data, HETLIOZ® may cause fetal harm. HETLIOZ® should be used during pregnancy only if the potential benefit justifies the potential risks. Caution should be exercised when HETLIOZ® is administered to a nursing woman.
  • HETLIOZ® has not been studied in patients with severe hepatic impairment and is not recommended in these patients.
  • Safety and effectiveness of HETLIOZ® in pediatric patients have not been established.

Please see full US Prescribing Information.